Navigation Links
Dragon announces new product launch; increase in annual production output capacity
Date:3/5/2008

VANCOUVER, March 5 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading international pharmaceutical company today announced the Company has increased its annual production capacity for its core products 7ACA and Clavulanic Acid by 30% and 56% respectively in order to meet increasing demand from its customers. Meanwhile, two new products Ceftazidime and Cefalexin, which were commercially launched in January 2008, have been added to Dragon's product portfolio.

In October 2007, Dragon successfully adopted an enzymatic process to its production of 7ACA. The enzymatic process is an environmentally friendly technology and the Company is now in the process of converting its entire production to incorporate this innovative technology. Once fully implemented, Dragon expects to further increase its manufacturing capacity from the current 600 tons to 780 tons yearly. The process will lower production costs by approximately 10% and additionally will reduce the amount of capital investment pertaining to environmental issues.

Annual production capacity of Clavulanic Acid has also been increased from 50 tons to 78 tons as a result of the addition of a new 120 ton capacity fermentor. As the first and largest producer of Clavulanic Acid in China, Dragon's sales have increased dramatically, rising from 16 tons in 2005 to 39 tons in 2007.

With a core business strategy to become a leading vertically integrated antibiotic drugs manufacturer, the Company will continuously broaden its product portfolio. In January 2008, Dragon successfully launched two new products, Ceftazidime and Cefalexin, to the Chinese market. Given the high demand for these drugs in the Chinese market, these two products are expected to become Dragon's growth driver in the coming years.

Ceftazidime is a third-generation cephalosporin antibiotic, a downstream product for 7ACA, and has broad-spectrum activity aga
'/>"/>

SOURCE Dragon Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dragon Announces R&D Achievement in Biotech Manufacturing Process
2. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
3. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
4. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
5. China Yingxia International Announces Q4 and FY 2007 Estimates
6. Bristol-Myers Squibb Announces Dividend
7. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
8. Maxygen Announces Management Changes
9. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
10. Exanet Announces ExaStore 2008 Clustered NAS System
11. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CASTLE ROCK, Colo. , May 23, 2013 /PRNewswire/ ... vitro diagnostic company focused on obtaining FDA clearance ... APPY1 , today announced the pricing of an underwritten ... and related warrants to purchase 3,500,000 shares of its ... share at a combined public offering price of $1.25 ...
(Date:5/23/2013)... N.Y. , May 23, 2013  BioScrip, Inc. ... Company will present at the Jefferies 2013 Global Healthcare ... Grand Hyatt New York. Richard ... Hai Tran , Chief Financial Officer, ... a.m. Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
(Date:5/23/2013)... NY (PRWEB) May 23, 2013 ... GRAPHALLOY® self-lubricating bushings mounted in stainless steel ... self-lubricating properties of GRAPHALLOY with the application and ... Stainless Steel Pillow Blocks work exceptionally well ... corrosive or hostile liquids such as acids, alkalies, ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3
... YORK, June 18 Danube Pharmaceuticals, Inc., a,privately ... development of innovative drugs for ophthalmology, is pleased,to ... MBA as its Chief,Executive Officer., "I am ... this,inflection point in its history as it advances ...
... CHESHIRE, Conn., June 18 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... Officer of Alexion Pharmaceuticals, will present at the,Jefferies & ... at 4:15,p.m., ET on Wednesday, June 25, 2008., ... available live. You can,access the webcast at: http://www.alexionpharm.com ...
... N.J., June 18 HemoCue(R) AB, a,global point-of-care ... Diagnostics Incorporated (NYSE: DGX ), today announced,that ... quantitative point-of-care,test for screening for, diagnosing and monitoring ... U.S. Food and Drug Administration (FDA). With,the FDA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
(Date:5/23/2013)... palsy with autologous cord blood. Following a cardiac arrest ... had been in a persistent vegetative state with ... with the cord blood containing stem cells, the symptoms ... to speak simple sentences and to move. "Our findings, ... long-held doubts about the effectiveness of the new therapy", ...
(Date:5/23/2013)... reveal the interplay of brain chemicals which help us ... and BBSRC. , By changing the way neurons ... While these changes can affect the strength of a ... that response. , Lead author Alex Thiele, ... others, you can make yourself better heard by speaking ...
Breaking Biology News(10 mins):Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... number of adults consuming sugar-sweetened beverages such as ... dramatically, according to a study led by researchers ... Health. Researchers examined changes over the past two ... representative survey data, and found that sugar-sweetened beverages ...
... University of Queensland could contribute to the development of ... Dengue fever. Led by Associate Professor Alexander ... Molecular and Microbial Sciences identified a novel characteristic of ... The team found all flaviviruses produced a small ...
... lead to a radical re-thinking about how the snowy ... of the adult females that we followed in a ... on the Arctic sea ice," said Universit Laval doctoral ... Gauthier as part of an International Polar Year (IPY) ...
Cached Biology News:Sweetened beverage consumption increases in the US 2UQ research targets West Nile virus and dengue fever 2Snowy owl -- a marine species? 2
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Mus musculus MARCKS-like protein, mRNA...
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... NEW HandyStep electronic from BRAND adds ... It is the only electronic, motor-driven ... syringe tips, including BRAND PD-Tip syringe ... Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. Select ...
Biology Products: